Von Willebrand Disease Clinical Trials 2023
Browse 6 Von Willebrand Disease Medical Studies Across 31 Cities
5 Phase 3 Trial · 43 Von Willebrand Disease Clinics
Reviewed by Michael Gill, B. Sc.
6 Von Willebrand Disease Clinical Trials Near Me
Top Hospitals for Von Willebrand Disease Clinical Trials
Bleeding and Clotting Disorders Institute
Peoria
2Active Trials
5All Time Trials for Von Willebrand Disease
2015First Von Willebrand Disease Trial
Cincinnati Children's Hospital Medical Center
Cincinnati
2Active Trials
3All Time Trials for Von Willebrand Disease
2017First Von Willebrand Disease Trial
Rainbow Babies and Children's Hospital
Cleveland
2Active Trials
2All Time Trials for Von Willebrand Disease
2017First Von Willebrand Disease Trial
Nationwide Children's Hospital
Columbus
2Active Trials
3All Time Trials for Von Willebrand Disease
2017First Von Willebrand Disease Trial
Top Cities for Von Willebrand Disease Clinical Trials
Von Willebrand Disease Clinical Trials by Phase of TrialPhase 1 Von Willebrand Disease Clinical Trials
Von Willebrand Disease Clinical Trials by Age Group1Active Von Willebrand Disease Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
< 18 Von Willebrand Disease Clinical Trials
Most Recent Von Willebrand Disease Clinical Trials2Active Von Willebrand Disease Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Treatment Name
Active Von Willebrand Disease Clinical Trials
All Time Trials for Von Willebrand Disease
First Recorded Von Willebrand Disease Trial
Open Label Emicizumab
1
1
2022
wilate
1
1
2021
rVWF plus TA
1
1
2021
rFVIII
1
1
2019
von Willebrand factor (Recombinant)
1
2
2017
Treatment
Year
Sponsor
efanesoctocog alfa (BIVV001)
2021
Bioverativ, a Sanofi company
Wilate
2020
Octapharma
About The Author
Michael Gill - B. Sc.
First Published: October 10th, 2021
Last Reviewed: August 21st, 2023
References1 Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10. https://pubmed.ncbi.nlm.nih.gov/286915572 Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769. https://pubmed.ncbi.nlm.nih.gov/272231463 Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jimenez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550. https://pubmed.ncbi.nlm.nih.gov/301573894 Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost. 2019 Sep;17(9):1470-1477. doi: 10.1111/jth.14491. Epub 2019 Jun 17. https://pubmed.ncbi.nlm.nih.gov/311242725 Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993 Dec;123(6):893-8. https://pubmed.ncbi.nlm.nih.gov/82295216 James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle B, McLintock C, McRae S, R Montgomery R, O'Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021 Jan 12;5(1):280-300. doi: 10.1182/bloodadvances.2020003265. https://pubmed.ncbi.nlm.nih.gov/335706517 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987 Feb;69(2):454-9. https://pubmed.ncbi.nlm.nih.gov/34922228 Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550. https://pubmed.ncbi.nlm.nih.gov/301573899 Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993 Dec;123(6):893-8. doi: 10.1016/s0022-3476(05)80384-1. https://pubmed.ncbi.nlm.nih.gov/822952110 Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia. 2007 Sep;13 Suppl 2:16-22. doi: 10.1111/j.1365-2516.2007.01501.x. https://pubmed.ncbi.nlm.nih.gov/17685919